Penile and Urethral Cancer News and Latest Research
- Phase 2 trial registered: TROP-2 ADC plus PD-1 inhibitor for advanced penile cancer Trial registered · ClinicalTrials.gov · 2026-10-30
A newly registered single-arm phase 2 trial (SCOPE) plans to evaluate sacituzumab tirumotecan plus toripalimab as chemo-free second-line therapy in platinum-refractory advanced penile squamous cell carcinoma, a setting where current options shrink tumors in only 10-15% of cases. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-01; planned enrollment 31; single site.
Why it matters: Penile cancer has few second-line options; this trial addresses an unmet need with a TROP-2 targeted ADC combination.
Urology clinical trials · Urology podcasts · Urology videos · Meetings · Daily edition archive
Loading today's edition…